Celgene reaches settlement with Actavis

Biopharmaceutical company Celgene has reached an agreement with Actavis that will terminate pending patent litigation over Abraxane (paclitaxel protein-bound particles for injectable suspension).

Abraxane is a chemotherapy drug that is used to treat breast cancer that has spread to other parts of the body. It can also be used to treat pancreatic cancer and certain types of lung cancer.

US patent numbers covering Abraxane include 7,758,891; 7,820,788; and 7,923,536. The patents are assigned to Abraxis BioScience, a company acquired by Celgene in 2010.

The settlement, which was announced on Friday, January 26, will see the parties file a consent judgment with the US District Court for the District of New Jersey to enjoin Actavis from selling a generic version of Abraxane until the patents expire. An inter partes review will also be terminated.

Celgene has provided Actavis with a licence to the patents from March 31, 2022.

In September 2016, LSIPR reported that India-based pharmaceutical company Glenmark had signed a drug agreement with Particle Sciences, a provider of drug development services, to develop, license and commercialise a generic version of Abraxane.

Submit a Comment

Your email address will not be published.

Subscribe to get the latest news